Skip to main content
Premium Trial:

Request an Annual Quote

Rebus Biosystems Acquires IP, Assay Assets of EEL Transcriptomics

NEW YORK – Rebus Biosystems said on Wednesday that it has acquired intellectual property and related assay assets of EEL Transcriptomics.

The enhanced electric, or EEL, fluorescence in situ hybridization assay will now be able to run on Rebus' Esper platform. In a statement, Rebus said the assay enables spatial transcriptomics in the human brain at single-cell resolution with the ability to scale to more than 5,000 genes.

Financial and other terms of the deal were not disclosed.

"This acquisition delivers on our promise to continue to expand the platform and enable research from discovery through clinical research," Rebus CEO Paul Sargeant said in a statement. "The EEL assay is highly synergistic with Rebus Esper’s Synthetic Aperture Optics technology."

EEL Transcriptomics was cofounded by Sten Linnarsson, a researcher at Sweden's Karolinska Institute and a Rebus scientific adviser, along with several other members of his lab.

The EEL assay will be available for use on the Esper system through early access in the first half of 2022, followed by a commercial launch in June, Rebus said.